Image from Kraskovskaya et al
Who Should Avoid BPC-157 Anyone with active, suspected, or a strong personal/family history of cancer, given the pro-angiogenic mechanism
This is a cellular "clean-up" mechanism where your body identifies weak, damaged mitochondria and recycles them
At the 5:1:1 ratio, daily glow peptide administration provides approximately 330mcg BPC-157, falling squarely within established effective ranges
It has been studied extensively for immune modulation across various conditions, from hepatitis B and C to cancer immunotherapy to vaccine enhancement in elderly populations
Topical glutathione formulations also exist but are widely considered the least effective delivery method because glutathione molecules are too large to penetrate the skin effectively in their intact form